Challenges in Developing GMP-Compliant Manufacturing Facilities for CAR-T Cells

In by

Spotlight Article


Lothar Germeroth

Latest Advances in CAR-T Cell Manufacture & Clinical Developments

Lothar Germeroth is Senior Vice President Juno Therapeutics, Inc. and Managing Director Juno Therapeutics GmbH. Dr Germeroth has over 25 years of management experience in the field of biotechnology. Most recently, Dr Germeroth served as the CEO at IBA GmbH and the COO at Stage Cell Therapeutics GmbH, and served eight years as CEO in three different German Biotech companies (Jerini BioTools GmbH, Chemotopix GmbH, Cytos Proteome Therapeutics GmbH) and as Chief Business Officer at Cytos Biotechnology AG in Switzerland. Dr Germeroth studied chemistry in Frankfurt/Main and obtained his PhD in Biochemistry in the department of Nobel Prize Laureate Professor Hartmut Michel at the Max-Planck Institute of Biophysics in Frankfurt.

DOI: 10.18609/cgti.2018.044
Citation: Cell Gene Therapy Insights 2018; 4(4), 431-436.
Open access

This content is restricted to registered users. Click here to Register or Login here.